TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION
FUN-HSC aims to identify and mimic maturation pathways of hematopoietic stem cells from pluripotent stem cells to create a reliable, clinically valuable source for diverse therapies.
Projectdetails
Introduction
Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have recently found broadened applications to gene and cell therapy, against other cancers, genetic, autoimmune, and infectious diseases.
Challenges in HSC Therapy
Nonetheless, practical limitations, such as donor-matching or insufficient cell number, render these therapies unfeasible or unsuccessful for many patients. Attempts to overcome these limitations have been unable to create a reliable source of HSC for patients.
Current Research on HSC Generation
While we can generate human HSC from pluripotent stem cells (PSC), they resemble early development stages, lacking the functional maturation hallmarks. FUN-HSC aims at identifying core and actionable maturation pathways for HSCs and at defining the contribution of coordinated gene expression by chromatin regulation, using a combination of functional and genetic screening technologies and high-throughput readouts in vitro and in vivo.
HSC Maturation Process
HSC maturation occurs in the liver during fetal development and confers functional multilineage hematopoiesis ability throughout adulthood. Using single cell omics analysis of human embryonic and fetal tissues, we describe multiple gene programs changing during developmental HSC maturation.
Research Methodology
This study will lead to candidate cell-intrinsic and niche-dependent instructions, which will be dissected in the context of the fetal liver by:
- Analyzing the cell compartments and their interactions.
- Combining novel organoid technologies with mouse xenografts to model the fetal liver environment.
Future Goals
Ultimately, we aim to identify a strategy that mimics these pathways in vitro to bring the maturation stage of the PSC-derived HSC to a robustly engraftable and clinically valuable HSC source.
Conclusion
Harnessing new knowledge in human HSC biology, cutting-edge genetics, and tissue technologies, FUN-HSC will provide great advances in the mission of making and maintaining HSCs in vitro, enabling their full therapeutic potential.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.265.684 |
Totale projectbegroting | € 2.265.684 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERASpenvoerder
- UNIVERSITY COLLEGE LONDON
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapiesThis project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies. | ERC Consolid... | € 2.000.000 | 2023 | Details |
How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantationRESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes. | ERC Starting... | € 1.500.000 | 2024 | Details |
Dissecting hepatocyte heterogeneity in liver growth to devise liver gene therapies for pediatric patientsHEPAGENE aims to understand hepatocyte heterogeneity and its role in liver growth to develop safe, effective gene therapies for pediatric metabolic diseases through advanced genetic engineering techniques. | ERC Consolid... | € 1.993.750 | 2025 | Details |
The impact of human aged bone marrow niche on human hematopoietic stem cell functionThis project aims to investigate how aging alters the human bone marrow niche and its impact on hematopoietic stem cell function to improve understanding and outcomes in elderly hematopoiesis. | ERC Starting... | € 1.500.000 | 2025 | Details |
Origins and Consequences of Hematopoietic Stem Cell MemoriesMemOriStem aims to uncover the origins and mechanisms of hematopoietic stem cell memories to enhance regenerative therapies for chronic inflammation, aging, and cancer. | ERC Starting... | € 1.500.000 | 2022 | Details |
Dissecting the molecular regulation of hematopoietic stem cell emergence using pluripotent stem cells to improve ex vivo therapies
This project aims to develop methods for generating and expanding hematopoietic stem cells from patient-specific induced pluripotent stem cells to overcome transplantation barriers and enhance therapies.
How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation
RESTART aims to enhance survival in pediatric HSCT by using multiomics to characterize human HSPC regeneration and identify predictors of adverse outcomes.
Dissecting hepatocyte heterogeneity in liver growth to devise liver gene therapies for pediatric patients
HEPAGENE aims to understand hepatocyte heterogeneity and its role in liver growth to develop safe, effective gene therapies for pediatric metabolic diseases through advanced genetic engineering techniques.
The impact of human aged bone marrow niche on human hematopoietic stem cell function
This project aims to investigate how aging alters the human bone marrow niche and its impact on hematopoietic stem cell function to improve understanding and outcomes in elderly hematopoiesis.
Origins and Consequences of Hematopoietic Stem Cell Memories
MemOriStem aims to uncover the origins and mechanisms of hematopoietic stem cell memories to enhance regenerative therapies for chronic inflammation, aging, and cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical applicationThis project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer. | EIC Pathfinder | € 3.797.562 | 2022 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
AI-powered platform for autologous iPSC manufacturingThe project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration. | EIC Pathfinder | € 3.999.225 | 2022 | Details |
PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cellsThis project aims to develop an automated high-throughput PEN photoporation system for safely and efficiently genetically modifying T cells and MSCs for cancer therapy commercialization. | EIC Transition | € 2.497.711 | 2024 | Details |
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
AI-powered platform for autologous iPSC manufacturing
The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.
PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells
This project aims to develop an automated high-throughput PEN photoporation system for safely and efficiently genetically modifying T cells and MSCs for cancer therapy commercialization.